Perspective Therapeutics expects Phase 3 trial in 2027
Among GEP-NET patients whose target lesions all expressed SSTR2, responses were reported in 14 of 38 Cohort 2 patients and eight of 17 Cohort 3 patients.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Perspective Therapeutics, Inc. (CATX) reported updated interim results from its Phase 1/2a study of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors. Objective response rates were 33% (15 of 46 patients) in Cohort 2 at 5.0 mCi and 50% (10 of 20) in Cohort 3 at 6.0 mCi. The rates include confirmed and unconfirmed responses; the Cohort 3 figure includes two additional unconfirmed partial responses reported as of September 10, 2026. Disease control rates were 89% and 95%, respectively. Progression-free survival across all three cohorts was 86% at six months, 74% at 12 months and 72% at 18 months.
No dose-limiting toxicities, Grade 4 or 5 treatment-emergent adverse events, or adverse event-related treatment discontinuations were reported. Grade 3 treatment-emergent adverse events occurred in 20 of 68 patients (29%), including Grade 3 renal events in two patients (2.9%). Perspective aims to complete Phase 3 site start-up preparations around year-end 2026, with site activation following an End-of-Phase 2 meeting with the FDA and Phase 3 initiation expected in 2027.
8-K Event Classification
Key Figures
Key Terms
objective response rate (ORR) medical
disease control rate (DCR) medical
progression-free survival (PFS) medical
dose-limiting toxicities (DLTs) medical
treatment-emergent adverse events (TEAEs) medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were CATX's VMT-α-NET response rates?
What were CATX's VMT-α-NET response rates in GEP-NET patients whose target lesions all expressed SSTR2?
What progression-free survival rates did CATX report for VMT-α-NET?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On October 23, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release and posted to its website a presentation announcing updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for the treatment and diagnosis of patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors that are being presented at the European Society for Medical Oncology Congress 2026 taking place October 23-27, 2026 in Madrid, Spain. A copy of the press release is filed herewith as Exhibit 99.1, and a copy of the presentation is filed herewith as Exhibit 99.2, and each is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
99.1 |
|
Press Release dated October 23, 2026. |
99.2 |
|
Presentation. |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
PERSPECTIVE THERAPEUTICS, INC. |
|
|
|
|
Date: |
October 23, 2026 |
By: |
/s/ Johan (Thijs) Spoor |
|
|
|
Johan (Thijs) Spoor |
Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
SEATTLE, Oct. 23, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced new interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). These data are being presented as a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026 in Madrid, Spain.
Neuroendocrine tumors are diagnosed in more than 12,000 people in the United States each year, and approximately 90% of gastroenteropancreatic (GEP) NETs express SSTR2, the target of [²¹²Pb]VMT-α-NET. In the ongoing Phase 1/2a study in patients with SSTR2-positive NETs who had not received prior radiopharmaceutical therapy, the objective response rate (ORR), including unconfirmed responses, was 33% in Cohort 2 (5.0 mCi, n=46) and 50% in Cohort 3 (6.0 mCi, n=20, as of September 10, 2026). For GEP-NETs patients with SSTR2 expression in all target lesions, responses were seen in 14 (37%) of 38 Cohort 2 patients, and in eight (47%) of 17 Cohort 3 patients. Disease control rate (DCR) was 89% and 95% in Cohorts 2 and 3, respectively, and progression-free survival (PFS) was 72% at 18 months across all cohorts. No dose-limiting toxicities (DLTs), Grade 4 or 5 treatment-emergent adverse events (TEAEs), or adverse event-related treatment discontinuations were reported. We aim to complete Phase 3 site start-up preparations around year-end 2026, positioning us to rapidly activate clinical sites following an End-of-Phase 2 meeting with the FDA, with Phase 3 initiation expected in 2027.
“These interim results reinforce the potential of VMT-α-NET to achieve a best-in-class profile, with robust tumor response, durable disease control and low incidence of high-grade adverse events,” said Thijs Spoor, Perspective’s Chief Executive Officer. “Success in radiopharmaceuticals requires a broad therapeutic window, and these data show our platform delivers: potent alpha radiation concentrated in the tumor, with tolerability that holds up across dose levels. Preparations for our first potential Phase 3 study are advancing, and we look forward to discussing the development plan with the FDA as we work toward the next stage of development.”
“These data from a substantially larger group of patients and longer follow-up provide a more comprehensive understanding of the clinical profile of VMT-α-NET,” said Markus Puhlmann, Perspective’s Chief Medical Officer. “We are very pleased with the evidence of sustained disease control alongside an encouraging safety profile observed to date, supporting VMT-α-NET’s potential in patients with SSTR2-positive neuroendocrine tumors. With regulatory engagement underway and manufacturing capacity scaling in parallel, we’re working to bring a potentially transformative new option to patients who need more choices.”
ESMO presentation based on analysis of 68 patients across three dose cohorts
The presentation provided initial cohort-level safety data in Cohorts 1, 2, and 3 of the study, as well as updated efficacy results from both patients in Cohort 1 (up to four treatments with 2.5 mCi of [²¹²Pb]VMT-α-NET), and initial results from all 46 patients in Cohort 2 (up to four treatments with 5.0 mCi) and all 20 patients in Cohort 3 (up to four treatments with 6.0 mCi). The analysis data cut-off date was September 2, 2026, approximately 20 weeks after the ASCO 2026 data cut-off date.
Efficacy: Objective responses in Cohorts 2 and 3, with disease control in at least 89% of patients in each cohort
|
Cohort 1 2.5 mCi (n=2) |
Cohort 2 5.0 mCi (n=46) |
Cohort 3 6.0 mCi (n=20) |
Objective response rate |
0 of 2 (0%) |
15 of 46 (33%) |
10 of 20 (50%)* |
Disease control rate |
2 of 2 (100%) |
41 of 46 (89%) |
19 of 20 (95%) |
Objective response rate in GEP-NET patients whose target lesions all express SSTR2 |
0 of 2 (0%) |
14 of 38 (37%) |
8 of 17 (47%)* |
*Includes two additional unconfirmed partial responses reported as of September 10, 2026. Objective response rate includes confirmed and unconfirmed responses. Disease control rate includes complete response, partial response, and stable disease. Cohort size and follow-up differ across cohorts.
Safety: No dose-limiting toxicities and no discontinuations due to adverse events
Additional data presentations at upcoming conferences
The Company will present additional data in the coming weeks: at the NANETS 2026 Multidisciplinary NET Medical Symposium, November 5, 2026, and the EORTC-NCI-AACR (ENA) Symposium, November 20, 2026.
Conference call today
Perspective will webcast a conference call today at 2 pm EDT / 8 pm CEST to discuss the data presented at the ESMO Congress 2026. Webcast details are available on the Events page of the Company's website. A question-and-answer session will follow the formal presentation.
About [²¹²Pb]VMT-α-NET
Perspective designed [212Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT).
About Neuroendocrine Tumors
Neuroendocrine tumors form in cells that interact with the nervous system or in glands that produce hormones. They can originate in various parts of the body, most often in the gut or the lungs, and can be benign or malignant. Neuroendocrine tumors are typically classified as pancreatic neuroendocrine tumors or non-pancreatic neuroendocrine tumors. According to cancer.net, it is estimated that more than 12,000 people in the United States are diagnosed with a NET each year. Importantly, neuroendocrine tumors are associated with a relatively long duration of survival compared to other tumors, and as a result, there are over 250,000 people living with this diagnosis.1
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.
The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).
The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s proprietary technology, imaging techniques and product candidates, including VMT-α-NET, PSV359, and VMT01, and related treatment opportunities in connection therewith; the Company’s understanding regarding the clinical profiles of its product candidates, including VMT-α-NET, PSV359, and VMT01; the Company’s belief that interim data reinforce the best-in-class potential of VMT-α-NET; the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the anticipated clinical benefits of the Company’s product candidates relative to existing therapies; the Company’s expectations regarding regulatory engagement and pathways for its product candidates; the Company’s expectations regarding its interactions with regulatory agencies, including the FDA, and the expected timing thereof; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include (without limitation) that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; regulatory authorities may not grant or may delay approval for our product candidates; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; the Company’s ability to successfully prepare for and initiate a registrational Phase 3 clinical trial of VMT-α-NET, including whether the FDA agrees with the Company’s proposed Phase 3 development plan; whether the Company will be able to initiate the anticipated Phase 3 trial in 2027; the Company’s ability to establish, maintain and expand its regional distribution and manufacturing capabilities; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com
|
1Dasari A et al. JAMA Netw Open 2025;8:e2515798. |
Ongoing Phase 1/2a to Establish Broad Therapeutic Window for Bamzireotide Navoxetan
